Improved tumor accumulation and therapeutic efficacy of CTLA-4-blocking antibody using liposome-encapsulated antibody: In vitro and in vivo studies.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Nanomedicine : nanotechnology, biology, and medicine

• Publication date

  2017-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.nano.2017.08.010PMID 28847682
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immune Checkpoint Blockade in Cancer Therapy.

  2015cited by this paper
• Nanoliposome-mediated targeting of antibodies to tumors: IVIG antibodies as a model.

  2015cited by this paper
• Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data

  2015cited by this paper
• Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

  2015cited by this paper
• Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.

  2015cited by this paper
• Nano Liposomes Labeled with 99mTc-HMPAO, a Novel Agent for Blood Pool Imaging

  2015cited by this paper
• Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.

  2015cited by this paper
• The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma.

  2014cited by this paper
• Sphingomyelin Liposomes Containing Soluble Leishmania major antigens Induced Strong Th2 Immune Response in BALB/c Mice

  2013cited by this paper
• Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell–Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects

  2013cited by this paper
• CTLA-4 blockade in tumor models: an overview of preclinical and translational research.

  2013cited by this paper
• Recent Trends in Multifunctional Liposomal Nanocarriers for Enhanced Tumor Targeting

  2013cited by this paper
• Antibody therapy of cancer

  2012cited by this paper
• Doxil®--the first FDA-approved nano-drug: lessons learned.

  2012cited by this paper
• Immunotherapies: The Blockade of Inhibitory Signals

  2012cited by this paper
• The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect.

  2011cited by this paper
• Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production

  2011cited by this paper
• PET imaging of EGFR expression in nude mice bearing MDA-MB-468, a human breast adenocarcinoma

  2011cited by this paper
• Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy

  2011cited by this paper
• The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy.

  2011cited by this paper
• Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma

  2011cited by this paper
• The safety and side effects of monoclonal antibodies

  2010cited by this paper
• Delivering nanomedicine to solid tumors

  2010cited by this paper
• Monoclonal antibodies for cancer immunotherapy.

  2009cited by this paper
• Disterolphospholipids: nonexchangeable lipids and their application to liposomal drug delivery.

  2009cited by this paper
• CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.

  2008cited by this paper
• Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.

  2007cited by this paper
• Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes.

  2006cited by this paper
• CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.

  2006cited by this paper
• Biodistribution of liposome‐entrapped human gamma‐globulin

  2006cited by this paper
• A NEW MONOCLONAL ANTIBODY RADIOPHARMACEUTICAL FOR RADIOIMMUNOSCINTIGRAPHY OF BREAST CANCER: DIRECT LABELING OF ANTIBODY AND ITS QUALITY CONTROL

  2006cited by this paper
• Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

  2004cited by this paper
• Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome.

  2004cited by this paper
• Pulmonary administration of IgG loaded liposomes for passive immunoprophylaxy.

  2003cited by this paper
• The B7–CD28 superfamily

  2002cited by this paper
• TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis.

  1998cited by this paper
• A New Look at Lipid-Membrane Structure in Relation to Drug Research

  1998cited by this paper
• CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

  1995cited by this paper
• Protection against doxorubicin‐induced alopecia in rats by liposome‐entrapped monoclonal antibodies

  1994cited by this paper
• Enhanced protection against respiratory influenza A infection in mice by liposome-encapsulated antibody.

  1994cited by this paper
• Encapsulation of chicken egg yolk immunoglobulin G (IgY) by liposomes.

  1993cited by this paper
• A simple method for producing a technetium-99m-labeled liposome which is stable in vivo.

  1992cited by this paper
• Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes

  1990cited by this paper
• Phosphorus assay in column chromatography.

  1959cited by this paper

• Site-specific targeting in immunoliposomal nanomedicine for oncology: opportunities and limitations.

  2026cites this paper
• A comprehensive review of using nanomaterials in cancer immunotherapy: Pros and Cons of clinical usage

  2025cites this paper
• Liposomes as Immunotherapeutic Carriers: A Game-Changer in Cancer Therapy

  2025cites this paper
• Subcutaneous Liposomal Delivery Improves Monoclonal Antibody Pharmacokinetics in vivo.

  2025cites this paper
• Biodistribution of 89Zr-Radiolabeled Nanoassemblies for Monoclonal Antibody Delivery Revealed through In Vivo PET Imaging

  2025cites this paper
• Advanced nanotechnology in enhancing immune checkpoint inhibitors (ICIs) for head and neck cancer therapy

  2025cites this paper
• Thermosensitive hydrogel containing liposomal nanoparticles of deferoxamine and curcumin: In vitro evaluation and diabetic wound healing effect in rats.

  2025cites this paper
• Nanomedicines for the treatment of genitourinary neoplasms

  2025cites this paper
• Nanoparticles for Cancer Immunotherapy: Innovations and Challenges

  2025cites this paper
• Green Nanocarriers and Biodegradable Systems for Sustainable Drug Delivery Solutions

  2025cites this paper
• pH-sensitive polymeric micelles enhance the co-delivery of doxorubicin and docetaxel: an emerging modality for treating breast cancer

  2024cites this paper
• All-Rounder Liposomes in Cancer Immunotherapy: Strategies and Design Applications of Engineered Liposomal Nanomaterials

  2024cites this paper
• Lipid-based nanosystems: the next generation of cancer immune therapy

  2024cites this paper
• Unleashing the potential of natural protein based nanoparticles for the delivery of therapeutic nucleic Acid: A comprehensive review.

  2024cites this paper
• Lipid-based nanoparticles for cancer immunotherapy

  2023cites this paper
• Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy

  2023cites this paper
• Enhancing Skin Cancer Immunotheranostics and Precision Medicine through Functionalized Nanomodulators and Nanosensors: Recent Development and Prospects

  2023cites this paper
• Dual blockage of both PD-L1 and CD47 enhances the therapeutic effect of oxaliplatin and FOLFOX in CT-26 mice tumor model

  2023cites this paper
• Personalized Cancer Nanomedicine: Overcoming Biological Barriers for Intracellular Delivery of Biopharmaceuticals

  2023cites this paper
• Drug delivery methods for cancer immunotherapy

  2023cites this paper
• Nano-constructs targeting the primary cellular energy source of cancer cells for modulating tumor progression

  2022cites this paper
• Recent advances in the liposomal nanovesicles based immunotherapy in the treatment of cancer: A review

  2022cites this paper
• Combinatorial Therapeutic Approaches with Nanomaterial-Based Photodynamic Cancer Therapy

  2022cites this paper
• Antibody‐Incorporated Nanomedicines for Cancer Therapy

  2022cites this paper
• Docetaxel in combination with metformin enhances antitumour efficacy in metastatic breast carcinoma models: a promising cancer targeting based on PEGylated liposomes.

  2022cites this paper
• Combinatorial therapeutic approaches of photodynamic therapy and immune checkpoint blockade for colon cancer treatment

  2022cites this paper
• Research advances in nanomedicine applied to the systemic treatment of colorectal cancer

  2022cites this paper
• In vivo study of anticancer activity of ginsenoside Rh2-containing arginine-reduced graphene in a mouse model of breast cancer

  2022cites this paper
• Nanomaterial-Based Drug Delivery Systems: A New Weapon for Cancer Immunotherapy

  2022cites this paper
• Nanotechnologies for the delivery of biologicals: historical perspective and current landscape.

  2021cites this paper
• Improving anti-tumour efficacy of PEGylated liposomal doxorubicin by dual targeting of tumour cells and tumour endothelial cells using anti-p32 CGKRK peptide

  2021cites this paper
• Preventive Cancer Vaccination by P5 HER-2/neo Derived Peptide-pulsed Peripheral Blood Mononuclear Cells in Mouse Model of Breast Cancer.

  2021cites this paper
• Emerging nanotechnological strategies to reshape tumor microenvironment for enhanced therapeutic outcomes of cancer immunotherapy

  2021cites this paper
• Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy

  2021cites this paper
• Emerging Trends in Immunomodulatory Nanomaterials Toward Cancer Therapy

  2021cites this paper
• Electrokinetic oscillation, railing, and enrichment of submicron particles along 3D microelectrode tracks

  2021cites this paper
• Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy.

  2021cites this paper
• Preparation of nanoliposomes containing HER2/neu (P5+435) peptide and evaluation of their immune responses and anti-tumoral effects as a prophylactic vaccine against breast cancer

  2020cites this paper
• Docetaxel delivery using folate-targeted liposomes: in vitro and in vivo studies

  2020cites this paper
• Liposome-Based Drug Delivery Systems in Cancer Immunotherapy

  2020cites this paper
• Nanotechnology-based platforms to improve immune checkpoint blockade efficacy in cancer therapy.

  2020cites this paper
• Photo-Polymerizable ferrous sulfate liposomes as vehicles for Iron fortification of food.

  2020cites this paper
• Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy

  2020cites this paper
• Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery

  2020cites this paper
• Folate targeted PEGylated liposomes for the oral delivery of insulin: In vitro and in vivo studies.

  2020cites this paper
• Synergistic effects of anti-PDL-1 with ablative radiation comparing to other regimens with same biological effect dose based on different immunogenic response

  2020cites this paper
• Optimization of Docetaxel Loading Conditions in Liposomes: proposing potential products for metastatic breast carcinoma chemotherapy

  2020cites this paper
• Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer.

  2020cites this paper
• Advanced biomaterials for cancer immunotherapy

  2020cites this paper
• Advancing Cancer Immunotherapies with Nanotechnology

  2019cites this paper
• Advanced liposome-loaded scaffolds for therapeutic and tissue engineering applications.

  2019cites this paper
• Overview of recent advances in liposomal nanoparticle-based cancer immunotherapy

  2019cites this paper
• Recent development in biodegradable nanovehicle delivery system-assisted immunotherapy.

  2019cites this paper
• Cell cytotoxicity, immunostimulatory and antitumor effects of lipid content of liposomal delivery platforms in cancer immunotherapies. A comprehensive in-vivo and in-vitro study.

  2019cites this paper
• Nanomedicine-based formulations containing ω-3 polyunsaturated fatty acids: potential application in cardiovascular and neoplastic diseases

  2019cites this paper
• MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer.

  2019cites this paper
• P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer

  2019cites this paper
• Nanoparticle drug delivery systems: an excellent carrier for tumor peptide vaccines

  2018cites this paper
• Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy?

  2018cites this paper
• Liposomal CpG‐ODN: An in vitro and in vivo study on macrophage subtypes responses, biodistribution and subsequent therapeutic efficacy in mice models of cancers

  2018cites this paper